Publications

Most recent publications

1. Selective and potent PROTAC degraders of c-Src kinase. Wuxiang Mao, Nathalie M. Vandecan, Christopher R. Bingham, Pui Ki Tsang, Peter Ulintz, Rachel Sexton, Daniel A. Bochar, Sofia D. Merajver, Matthew B. Soellner (2023). ACS Chem Biol. PMID: 38113191.

2. Conformation-tunable ATP-competitive kinase inhibitors. Michael P. Agius, Kristin Ko, Taylor K. Johnson, Sameer Phadke, Matthew B. Soellner  (2022). Chem. Commun., 58, 3541-3544. 

3. Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase. Taylor K Johnson, Daniel A Bochar, Nathalie M Vandecan, Jessica Furtado, Michael P Agius, Sameer Phadke, Matthew B Soellner (2021). Angew Chem Int Ed Engl. 60(37):20196-20199. PMCID: PMC8405588.

4. Insights into the modular design of kinase inhibitors and application to Abl and Axl. Sameer Phadke, Lluis Lopez-Barcons, Nathalie Vandecan, Zhifen Wu, Taylor K. Johnson, Eric J. Lachacz, Sofia D. Merajver, Matthew B. Soellner  (2021). RSC Med. Chem., 2022,13, 64-71. 

5. MEK is a promising target in the basal subtype of bladder cancer. Nathan M. Merrill, Nathalie M. Vandecan, Kathleen C. Day, Phillip L. Palmbos, Mark L. Day, Aaron M. Udager, Sofia D. Merajver, Matthew B. Soellner (2021). Oncotarget 11(44): 3921–3932. PMCID: PMC7646827

High quality, selective kinase inhibitors made freely available to the science community

1. Development of a highly selective c-Src kinase inhibitor. Kristoffer R. Brandvold, Michael E. Steffey, Christel C. Fox, and Matthew B. Soellner (2012). ACS Chemical Biology 7, 1393–1398. PMCID: PMC3423592. 

2. Irreversible inhibitors of c-Src kinase that target a nonconserved cysteine. Frank E. Kwarcinski, Christel C. Fox, Michael E. Steffey, and Matthew B. Soellner (2012). ACS Chemical Biology 7, 1910–1917. PMCID: PMC3500393. 

3. Exquisitely specific bisubstrate inhibitors of c-Src kinase. Kristoffer R. Brandvold, Shana M. Santos, Meghan E. Breen, Eric J. Lachacz, Michael E. Steffey, and Matthew B. Soellner (2015). ACS Chemical Biology 10, 1387–1391. 

Biological evaluation of potential therapeutics for TNBC

1. Synthesis and biological evaluation of lactimidomycin and its analogues. Brian J. Larsen, Zhankui Sun, Eric Lachacz, Yaroslav Khomutnyk, Matthew B. Soellner*, and Pavel Nagorny* *co-corresponding authors (2015). Chemistry: A European Journal 21, 19159–19167.

2. Molecular determinants of drug response in TNBC cells. Nathan M. Merrill, Eric J. Lachacz, Nathalie M. Vandecan, Peter J. Ulintz, LiWei Bao, John P. Lloyd, Joel A. Yates, Aki Morikawa, Sofia D. Merajver and Matthew B. Soellner (2019). Breast Cancer Research & Treatment doi: 10.1007/s10549-019-05473-9. 

Methodologies to design novel kinase inhibitors

1. Activation state-selective kinase inhibitor assay based on ion mobility-mass spectroscopy. Jessica N. Rabuck, Suk-Joon Hyung, Christel C. Fox, and Matthew B. Soellner*, and Brandon T. Ruotolo* *co-corresponding authors (2013). Analytical Chemistry 85, 6995–7002. PMCID: PMC3784979. 

2. Development of a chimeric c-Src kinase and HDAC inhibitor. Kristin S. Ko, Michael E. Steffey, Kristoffer R. Brandvold, and Matthew B. Soellner (2013). ACS Medicinal Chemistry Letters 4, 779–783. PMCID: PMC3763859.

3. Substrate activity screening for kinases: Discovery of small molecule substrate-competitive c-Src inhibitors. Meghan E. Breen, Michael E. Steffey, Eric J. Lachacz, Frank E. Kwarcinski, Christel C. Fox, and Matthew B. Soellner (2014). Angewandte Chemie 53, 7010–7013. PMCID: PMC4108202.

4. Discovery of bivalent kinase inhibitors via enzyme-templated fragment elaboration. Frank E. Kwarcinski, Michael E. Steffey, Christel C. Fox, and Matthew B. Soellner (2015). ACS Medicinal Chemistry Letters 6, 898–901. 

5. Selective proteolysis to study the global conformation and regulatory mechanisms of c-Src kinase. Michael P. Agius, Kristin S. Ko, Taylor K. Johnson, Frank E. Kwarcinski, Sameer Phadke, Eric J. Lachacz, and Matthew B. Soellner (2019). ACS Chemical Biology, 14, 7, 1556-1563. PMCID: PMC7254491.